GlassScriptPhysician profile
Brandon Mullins
NPI 1760863310
$8,040.62
in general payments reported to CMS, 2019-2025
43 companies · $2,737 in 2025
The $2,737 reported for 2025 was more than what 92% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $215 · 2021: $828 · 2022: $1,204 · 2023: $1,145 · 2024: $1,912 · 2025: $2,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,647 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $770 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,647.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $770.00 |
| Education | $376.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,397.40 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $900.18 | 2021-2025 | Tagrisso, Lynparza, Imfinzi |
| Siemens Medical Solutions USA, INC. | $770.00 | 2025 | |
| Incyte Corporation | $629.51 | 2020-2025 | Jakafi, Zynyz, Monjuvi |
| Novartis Pharmaceuticals Corporation | $402.85 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $346.48 | 2021-2025 | |
| Abbvie INC. | $341.31 | 2021-2025 | |
| Pfizer INC. | $302.51 | 2020-2025 | |
| Lilly USA, LLC | $294.50 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $293.48 | 2021-2025 | Keytruda, Lynparza, Lenvima |
| Glaxosmithkline, LLC. | $263.19 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Sanofi-Aventis U.S. LLC | $177.94 | 2021-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $150.35 | 2020-2023 | Imbruvica |
| Daiichi Sankyo INC. | $135.34 | 2024-2025 | Enhertu, Datroway |
| Sumitomo Pharma America, INC. | $134.39 | 2023-2024 | Orgovyx |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $128.28 | 2020-2022 | |
| Servier Pharmaceuticals LLC | $110.40 | 2022-2025 | |
| Beigene USA, INC. | $103.52 | 2021-2024 | Brukinsa |
| Myovant Sciences INC. | $92.82 | 2022 | |
| Amgen INC. | $84.63 | 2020-2023 | Kyprolis |
| Blueprint Medicines Corporation | $84.13 | 2023-2024 | Ayvakit |
| Progenics Pharmaceuticals, INC. | $78.36 | 2023-2024 | Pylarify |
| Karyopharm Therapeutics INC. | $66.44 | 2022-2025 | Xpovio |
| Seagen INC. | $62.14 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $59.34 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.09 | 2022-2024 | Ninlaro |
| Novocure INC. | $57.64 | 2021-2025 | Optune, Optune Gio |
| Coherus Oncology, INC. | $55.75 | 2021-2024 | |
| Caris Mpi, INC. | $55.50 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $44.45 | 2024 | Tecentriq Hybreza, Columvi, Polivy |
| Astellas Pharma US INC | $43.91 | 2024-2025 | Xtandi, Xospata |
| Sobi, INC | $40.33 | 2023 | |
| Exelixis INC. | $34.33 | 2020-2023 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $33.47 | 2021 | |
| Puma Biotechnology, INC. | $30.26 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $26.59 | 2020-2021 | |
| Legend Biotech USA INC. | $25.13 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $24.61 | 2023-2024 | Xarelto |
| Stemline Therapeutics INC. | $23.04 | 2023 | Orserdu |
| G1 Therapeutics, INC. | $20.66 | 2022 | |
| Beone Medicines USA, INC. | $20.57 | 2025 | Brukinsa |
| Tempus Ai, INC | $20.36 | 2024 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $15.44 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.